Ready-to-use AAV1 particles produced from pAAV-EF1a-iCreV (#140135). In addition to the viral particles, you will also receive purified pAAV-EF1a-iCreV plasmid DNA. EF1a-driven, light-inducible iCreV recombinase for spatiotemporally precise optogenomic modifications. These AAV preparations are suitable purity for injection into animals.

Ready-to-use AAV1 particles produced from pAAV-EF1a-iFlpV (#140137). In addition to the viral particles, you will also receive purified pAAV-EF1a-iFlpV plasmid DNA. EF1a-driven, light-inducible iFlpV recombinase for spatiotemporally precise optogenomic modifications. These AAV preparations are suitable purity for injection into animals.

Ready-to-use AAV1 particles produced from pAAV-EF1a-iDreV (#140136). In addition to the viral particles, you will also receive purified pAAV-EF1a-iDreV plasmid DNA. EF1a-driven, light-inducible iDreV recombinase for spatiotemporally precise optogenomic modifications. These AAV preparations are suitable purity for injection into animals.

Ready-to-use AAV PHP.eB particles produced from pAAV-EF1a-iCreV (#140135). In addition to the viral particles, you will also receive purified pAAV-EF1a-iCreV plasmid DNA. EF1a-driven, light-inducible iCreV recombinase for spatiotemporally precise optogenomic modifications. These AAV were produced with the PHPeB serotype, which permits efficient transduction of the central nervous system. These AAV preparations are suitable purity for injection into animals.

Ready-to-use AAV PHP.eB particles produced from pAAV-EF1a-iFlpV (#140137). In addition to the viral particles, you will also receive purified pAAV-EF1a-iFlpV plasmid DNA. EF1a-driven, light-inducible iFlpV recombinase for spatiotemporally precise optogenomic modifications. These AAV were produced with the PHPeB serotype, which permits efficient transduction of the central nervous system. These AAV preparations are suitable purity for injection into animals.

Ready-to-use AAV PHP.eB particles produced from pAAV-EF1a-iDreV (#140136). In addition to the viral particles, you will also receive purified pAAV-EF1a-iDreV plasmid DNA. EF1a-driven, light-inducible iDreV recombinase for spatiotemporally precise optogenomic modifications. These AAV were produced with the PHPeB serotype, which permits efficient transduction of the central nervous system. These AAV preparations are suitable purity for injection into animals.

Ready-to-use AAV PHP.eB particles produced from AiP11851-pAAV-hDLX-minBG-iCre-4X2C-WPRE3-BGHpA (Alias: CN1851) (#164450). In addition to the viral particles, you will also receive purified AiP11851-pAAV-hDLX-minBG-iCre-4X2C-WPRE3-BGHpA (Alias: CN1851) plasmid DNA. minBetaGlobin-driven expression of Cre in forebrain GABAergic interneurons. For use in combination with Cre-dependent transgenic mouse lines or co-infection with Cre dependent viral vectors. These AAV were produced with the PHPeB serotype, which permits efficient transduction of the central nervous system. These AAV preparations are suitable purity for injection into animals.

Ready-to-use AAV1 particles produced from pAAV-CAG-emiRFP670 (#197200). In addition to the viral particles, you will also receive purified pAAV-CAG-emiRFP670 plasmid DNA. CAG-driven expression of emiRFP670. These AAV preparations are suitable purity for injection into animals.

Ready-to-use AAV5 particles produced from pAAV.CAGFLEX.(cyto).iATPSnFR2.S29W.A95K.HaloTag (#209655). In addition to the viral particles, you will also receive purified pAAV.CAGFLEX.(cyto).iATPSnFR2.S29W.A95K.HaloTag plasmid DNA. CAG-driven, Cre-dependent expression of the high affinity ATP biosensor iATPSnFR2. These AAV preparations are suitable purity for injection into animals.

Ready-to-use AAV1 particles produced from pAAV.hSyn.iGluSnFR3.v857.GPI (#178331). In addition to the viral particles, you will also receive purified pAAV.hSyn.iGluSnFR3.v857.GPI plasmid DNA. Synapsin-driven, third generation glutamate sensor iGluSnFR3, variant 857. These AAV preparations are suitable purity for injection into animals.

Ready-to-use AAV1 particles produced from pAAV.hSyn.FLEX.iGluSnFR3.v857.GPI.codonopt (#175181). In addition to the viral particles, you will also receive purified pAAV.hSyn.FLEX.iGluSnFR3.v857.GPI.codonopt plasmid DNA. Synapsin-driven, Cre-dependent, third generation glutamate sensor iGluSnFR3, variant 857. These AAV preparations are suitable purity for injection into animals.

Ready-to-use AAV1 particles produced from AAV-hSyn-mCherry-P2A-Cre-WPRE (#107312). In addition to the viral particles, you will also receive purified AAV-hSyn-mCherry-P2A-Cre-WPRE plasmid DNA. hSyn-driven expression of mCherry and Cre (physically separate). These AAV preparations are suitable purity for injection into animals.

Ready-to-use AAV1 particles produced from pAAV.hSyn.iGluSnFR3.v857.PDGFR (#178329). In addition to the viral particles, you will also receive purified pAAV.hSyn.iGluSnFR3.v857.PDGFR plasmid DNA. Synapsin-driven, third generation glutamate sensor iGluSnFR3, variant 857. These AAV preparations are suitable purity for injection into animals.

Ready-to-use AAV1 particles produced from pAAV.hSyn.FLEX.iGluSnFR3.v857.PDGFR.codonopt (#175180). In addition to the viral particles, you will also receive purified pAAV.hSyn.FLEX.iGluSnFR3.v857.PDGFR.codonopt plasmid DNA. Synapsin-driven, Cre-dependent, iGluSnFR3 glutamate sensor. These AAV preparations are suitable purity for injection into animals.

Ready-to-use AAV9 particles produced from pAAV-CAG-FLEx-iSeroSnFR (#128486). In addition to the viral particles, you will also receive purified pAAV-CAG-FLEx-iSeroSnFR plasmid DNA. CAG driven, Cre-dependent expression of iSeroSnFR. These AAV preparations are suitable purity for injection into animals.

Ready-to-use AAV9 particles produced from pAAV-CAG-iSeroSnFR-Nlgn (#128485). In addition to the viral particles, you will also receive purified pAAV-CAG-iSeroSnFR-Nlgn plasmid DNA. CAG-driven expression of a fluorescent reporter for serotonin (localized to dendrites). These AAV preparations are suitable purity for injection into animals.

Ready-to-use AAV PHP.eB particles produced from AiP13779 - pAAV-AiE0779m_3xC2-minBG-iCre(R297T)-BGHpA (Alias: CN3779) (#199776). In addition to the viral particles, you will also receive purified AiP13779 - pAAV-AiE0779m_3xC2-minBG-iCre(R297T)-BGHpA (Alias: CN3779) plasmid DNA. Cre recombinase expression in striatal direct pathway medium spiny neurons (D1-MSNs). These AAV were produced with the PHPeB serotype, which permits efficient transduction of the central nervous system. These AAV preparations are suitable purity for injection into animals.

Ready-to-use AAV PHP.eB particles produced from AiP13044 - pAAV-AiE0779m_3xC2-minBG-SYFP2-WPRE3-BGHpA (Alias: CN3044) (#191706). In addition to the viral particles, you will also receive purified AiP13044 - pAAV-AiE0779m_3xC2-minBG-SYFP2-WPRE3-BGHpA (Alias: CN3044) plasmid DNA. SYFP2-expression in striatal direct pathway medium spiny neurons (D1-MSNs). These AAV were produced with the PHPeB serotype, which permits efficient transduction of the central nervous system. These AAV preparations are suitable purity for injection into animals.

Ready-to-use AAV PHP.eB particles produced from AiP13781 - pAAV-AiE0452h-minBG-iCre(R297T)-BGHpA (Alias: CN3781) (#199777). In addition to the viral particles, you will also receive purified AiP13781 - pAAV-AiE0452h-minBG-iCre(R297T)-BGHpA (Alias: CN3781) plasmid DNA. Cre recombinase expression in striatal indirect pathway medium spiny neurons (D2-MSNs). These AAV were produced with the PHPeB serotype, which permits efficient transduction of the central nervous system. These AAV preparations are suitable purity for injection into animals.

Ready-to-use AAV PHP.eB particles produced from AiP14361: pAAV-AiE0452h_3xC2-minBG-jGCaMP8s-WPRE3-BGHpA (Alias: CN4361) (#214857). In addition to the viral particles, you will also receive purified AiP14361: pAAV-AiE0452h_3xC2-minBG-jGCaMP8s-WPRE3-BGHpA (Alias: CN4361) plasmid DNA. minBG-driven expression of jGCaMP8s in striatal indirect pathway medium spiny neurons (D2 MSNs). These AAV were produced with the PHPeB serotype, which permits efficient transduction of the central nervous system. These AAV preparations are suitable purity for injection into animals.